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ABSTRACT 
Introduction. The vast majority of Non-Small Cell Lung Cancers (NSCLCs) presents as advanced 
disease and histological diagnosis is widely based on small samples. The differential activity and 
toxicity profile of new cytotoxic and molecular targeted therapies according to histotypes requires a 
precise subtyping of NSCLC. Immunohistochemistry (IHC) contributes to define the most probable 
histotype, however, the real impact of IHC characterization of NSCLC-Not Otherwise Specified 
(NOS) in terms of outcome is not well established. Methods. A large series of 224 advanced "non-
squamous" NSCLC diagnosed on small biopsy or cytological samples and homogeneously treated 
was retrospectively selected, all having adequate follow-up data available. Reviewed diagnoses 
resulting into two groups: adenocarcinoma (ADC) and NSCLC-NOS. The latter was further 
characterized by IHC (TTF-1, Napsin-A, p40 and Desmocollin-3) to identify a possible, most 
probable differentiation lineage. Results. 67% of cases were classified as ADC based on 
morphological examination only (“morphological ADC”) and 33% NSCLC-NOS. IHC profiling of 
NSCLC-NOS identified 43.2% of cases with an ADC immunophenotype (“NSCLC favor ADC”), 
10.8% with a phenotype favoring squamous lineage and 46% lacking differentiation features. 
Survival curves confirmed no difference in terms of outcome between the “morphological ADC” 
and the “NSCLC favor ADC” groups, while a significantly poorer outcome was found in the “null” 
group either in terms of best response, progression free and overall survival. Conclusion. Tumors 
with an IHC profile ADC-like had an overall survival comparable to that of “morphological 
ADCs”. These findings support the use of IHC to optimize lung cancer histological typing and 
therapy.  
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INTRODUCTION 
The majority of Non-Small Cell Lung Cancers (NSCLC) present at advanced stage and the 
histological definition is widely based on small biopsy or cytological samples. The differential 
activity and toxicity profile of new cytotoxic agents and molecular targeted therapies according to 
different lung cancer histotypes
1, 2
 led to an increased need for a precise NSCLC subtyping
3
 and the 
differentiation between adenocarcinoma (ADC) and squamous carcinoma (SQC) is the minimum 
requirement. Unfortunately, in most cases there are only limited amounts of tumor tissue obtained 
from primary or metastatic sites, generally through fine needle aspiration cytology or tiny 
bronchoscopic biopsies, available for pathological examination. This may hamper the precise tumor 
definition, either because of scant viable cells or poor tumor differentiation
4
. In such a context, 
morphological diagnostic criteria could fail, particularly in undifferentiated cancers. The 
ATS/ERS/IASLC guidelines recommend the use of immunohistochemistry (IHC) in biopsy 
samples when a precise morphology-based subtyping is not possible
5
. As a consequence, several 
studies proposed different panels of IHC markers, useful to identify the specific cell lineages. These 
IHC markers helped to distinguish SQC from ADC, not only in surgical material
6-8
, but also in 
cytology
9
 or biopsy samples
10-13
. Recently, our group demonstrated that a limited, four-marker 
panel (TTF1, p63, Desmocollin-3 and Napsin-A) could narrow the percentage of unclassified 
NSCLC-NOS from 36% to 14%, thus contributing to refine lung cancer classification in fine needle 
aspiration biopsies
14
. 
However, the real impact on the patients’ outcome of IHC-based subtyping of morphologically 
undifferentiated NSCLCs-Not Otherwise Specified (NOS), compared to the behavior of cases 
having morphology-driven diagnoses, has not been established. In the present study, we 
retrospectively analyzed a consecutive series of patients with advanced NSCLC and a non-
squamous histological diagnosis (ADC and NSCLC-NOS), candidate for first line treatment, for 
whom small biopsies or cytology specimens only were available. The group of lung cancers 
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subtyped by an IHC marker panel was correlated with two separate groups of morphology-only 
ADC and of NSCLC having a “null” phenotype (according to the markers used here), with respect 
to the response to treatment and outcome. 
 
MATERIALS AND METHODS 
Case selection. A cohort of 224 consecutive patients with advanced NSCLC (IIIB and IV stages, 
UICC TNM 6
th
 edition) diagnosed as non-squamous NSCLC (ADC or NSCLC-NOS) on small 
biopsy or cytological samples and treated at the Thoracic Oncology Unit of San Luigi Hospital 
(Orbassano-Turin, Italy) from 2005 to 2010 was retrospectively selected. All considered specimens 
were obtained from chemo-naive patients, who subsequently received first-line treatment; data on 
response and overall survival were available for all considered patients. Almost all patients received 
front-line platinum-based chemotherapy with/without experimental agents. Twelve patients with 
PS2 received single agent pemetrexed or erlotinib/gefitinib (n=2). Forty–one patients were treated 
second-line (n=22)/third line (n=19) erlotinib according to the registration label. For institutional 
policy in that period of time, patients with ADC or any other type of NSCLC were not routinely 
checked for Epidermal growth factor (EGFR) mutation or ALK translocation. 
All pathological diagnoses were reviewed (LR) and segregated into two groups: 1. ADC based on 
morphology only and 2. NSCLC-NOS. An external unrelated pathologist (GR) reviewed all the 
cases of this latter group confirming that they were all undifferentiated cases with no morphological 
criteria helpful to discriminate between adeno- or squamous differentiation. Furthermore, those 
cases with cytological characteristics suggestive of neuroendocrine differentiation (large cell with 
homogeneous salt-and-pepper chromatin appearance, large nucleoli, abundant granular cytoplasm) 
were excluded from the series and in those doubtful cases immunohistochemistry for 
neuroendocrine markers was performed to further exclude positive cases. The NSCLC-NOS group 
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was further analyzed for a tissue sparing, minimalist IHC approach (as previously described
14
) to 
better characterize any residual differentiation lineage.  
Immunohistochemistry. Five micron-thick serial sections were collected onto charged slides, 
dewaxed, rehydrated in pH 7.5 buffer, and processed for standard IHC staining. Briefly, after 
blocking endogenous peroxidase activity in 0.3% hydrogen peroxide and methanol solution for 15 
min, 5 micron-thick cell block sections were reacted for 40 minutes at room temperature with the 
nuclear markers TTF1 (MoAb clone 8G7, 1/100) and p40 (MoAb clone BC28, prediluted) in a first 
run and with the cytoplasmic marker Napsin A (MoAb clone TMU-Ad02, 1/100) and with the cell 
membrane desmosomal marker Desmocollin-3 (DSC3, MoAb clone DSC3, 1/30, overnight at 4°C). 
Slides were then incubated in a detection kit (EnVision Plus HRP, Dako) according to the 
manufacturer’s instructions, developing peroxidase activity with 3-3'-diaminobenzidine. Antigen 
retrieval was performed in a pressure cooker for five minutes at 125°C followed by a quick 10 
second step at 90°C using pH 8.0 EDTA buffer for all primary antibodies, and pH 6.6 citrate buffer 
for DSC-3. Finally, slides were counterstained with hematoxylin, dehydrated and mounted. The 
specificity of all immunoreactions was double-checked by substituting the primary antibody with a 
non-related isotypic mouse immunoglobulin at a comparable dilution, and with normal serum alone.  
All histological bioptical or cytological cell blocks were used for immunohistochemical reactions. 
Normal bronchial epithelium and alveolar epithelium were used as internal controls for basal and 
glandular markers, respectively. TTF1 and p40 were considered positive when a nuclear signal of 
any intensity was recorded; Napsin A was considered positive when a finely granular 
intracytoplasmic signal was found; DSC3 was considered positive in case of weak linear membrane 
signal. 
Statistical analyses. Qualitative data were compared by Fisher’s t test. Overall survival (OS) was 
defined as the time between the date of diagnosis and the last follow-up and/or death, and 
progression free survival (PFS) was calculated from the date of diagnosis to the date of clinical 
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and/or radiological progression to the first line treatment. Best response to therapy was recorded as 
complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD), 
following RECIST criteria
15,16
. Disease Control Rate (DCR) and Response Rate (RR) percentages 
were calculated on the basis of best responses. Survival estimates were calculated using the Kaplan-
Meier’s method and compared by the log rank test. Cox’s univariate survival analysis was 
performed to identify prognostic factors for both Progression Free Survival (PFS) and overall 
survival (OS). All analyses were performed using the GraphPad Prism statistical software. All P 
values were based on 2-sided test and considered as significant when less than 0.05, confidence 
intervals (CIs) at the 95% level. 
 
RESULTS 
Immunohistochemical subtyping. Patients’ characteristics are summarized in Table 1. After 
review, diagnoses were distributed as follows: 150/224 (67%) were ADC based on morphological 
examination only, while the other 74/224 (33%) were NSCLC-NOS (Figure 1). After applying a 
panel of four markers (TTF1, p40, DSC3 and NapsinA) the NSCLC-NOS group was further 
divided as follows: 32/74 (43.2%) cases resulted TTF1 and/or Napsin A positive (and p40/DSC3 
negative), and were subtyped as “NSCLC favor-ADC” based on a glandular immunophenotype; on 
the other hand, 8/74 (11%) cases resulted p40 and/or DSC3 positive (and TTF1/Napsin A negative), 
being subtyped as “NSCLC favor SQC” according to a squamous phenotype. This group was 
subsequently excluded from the statistical analyses due to the small number of cases and because 
this study was designed for "non-squamous" NSCLC to better understand the impact of diagnostic 
workup on therapeutic decision. Finally, 34/74 (46%) cases did not reveal any specific 
immunoprofile and were consequently classified as “NSCLC with a null phenotype” (including nine 
cases that remained “not otherwise specified” due to insufficient material for IHC). No significant 
correlations were found among groups and clinical-pathological characteristics.  
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Response to therapy and survival. Response rate (RR) and disease control rate (DCR) percentages 
were calculated for each group (Figure 2). In terms of response to therapy, the group of patients 
with a diagnosis of morphological ADC had 46 PR, 54 SD and 50 PD with a RR=31% and 
DCR=67%. The whole group of morphologically NSCLC-NOS had 28 PR, 18 SD and 28 PD with 
a RR=38% and DCR=62% with no significant difference between the two groups. However, after 
IHC, the subgroup of patients with a diagnosis of “NSCLC favor ADC” had 14 PR, 10 SD and 8 
PD with a RR=44% and a DCR=75%, a finding not significantly different from the group of 
“morphological ADC”. Conversely, the subgroup of NSCLC with a null immunophenotype had 12 
PR, 5 SD and 17 PD corresponding to a RR=35% and DCR=50% all significantly different either 
with the “morphological ADC” cohort (Chi-Square test, p=0.009) or the “NSCLC favor ADC” 
subgroup (Chi-Square p=0.01), or even the whole series of ADC differentiated tumors (with 
morphological or immunophenotypical ADC features) (Chi-Square test, p=0.006). 
In terms of outcome, the “morphological ADC” had a median PFS of 7.3 months, a median OS of 
12.3 months with 10/150 (6.7%) censored cases. On the other hand, the group of NSCLC-NOS had 
a median PFS of 5.9 months (HR= 0.6249; 95% CI=0.4571 to 0.8544, p=0.003) and a median OS 
of 9.6 months with only 1/74 (1.3%) censored case (HR= 0.5804; 95% CI= 0.4214 to 0.7995, 
p=0.0009) (Figure 3). After IHC, the “NSCLC-favor-ADC” cases had a median PFS of 7.05 
months, a median OS of 13.1 months and 1/32 (3.1%) censored case, while the group of “NSCLC-
null phenotype” had a median PFS of 3.8 months (log-rank test p<0.0001) and a median OS of 7.2 
months without censored cases (log rank test p<0.0001) (Figure 4A). Grouping together all the 
ADC differentiated tumors, a significant difference compared to the “NSCLC null phenotype” 
group was confirmed both in terms of PFS (HR= 0.2193; CI= 0.1149 to 0.4184, p<0.0001) and of 
OS (HR= 0.2819; CI= 0.1664 to 0.4773, p<0.0001) (Figure 4B). 
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In the  “morphological” ADC  subgroup, 20% of the patients received Erlotinib as second/third line, 
while the same agent was part of second/third line treatment in 22% of the NSCLC-NOS favor 
ADC and 12% of  the NSCLC “null” subgroups.  
 
DISCUSSION 
Data about the benefit of immunohistochemical subtyping in terms of disease outcome are still 
unclear
17
, even though there is the almost mandatory need for accurate histotyping of NSCLC 
because of the demonstrated efficacy of histology-driven treatment decision. In this study, we show 
that immunophenotyping of (poorly differentiated) NSCLC is a useful task in terms of therapeutic 
strategy. In fact, cases with an undefined morphology pattern but an immunophenotype that 
overlaps that of well differentiated adenocarcinoma (“NSCLC favor ADC” subgroup) have both 
response to chemotherapy and outcome similar to that of “morphology-only” ADC cases. In 
addition, in terms of response rate and survival, such treatment outcome was significantly different 
from the NSCLCs subgroup having a “null” phenotype. The latter followed a more aggressive 
course, possibly as the result of an undifferentiated nature of this subgroup of tumors. 
This study was restricted to patients with advanced NSCLC that underwent chemotherapy in a 
period of time (2005-2010) prior to European Medicine Agency (EMA) approval of pemetrexed 
(PEM) as first line treatment for advanced non-squamous-NSCLC and whose non-squamous 
carcinoma diagnoses were obtained on small biopsies or cytological samples. On the one side, a 
strength of this study is the homogeneous patient sample in terms of disease stage and pathological 
diagnoses, while one potential weakness may be its heterogeneity in terms of chemotherapy 
treatment options. However, this turned out to be irrelevant because the observed results (rather 
related to diagnostic workup and its impact on outcome), were independent from a specific 
chemotherapy regimen. Out of the initial cohort of 224 consecutive carcinomas, 74/224 (33%) 
could not be characterized on the basis of morphological features alone, and remained NSCLC-
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NOS. These two groups did not differ in terms of best response to therapy but only in terms of PFS 
or OS. It could be argued that the use of EGFR–TKI, in front or subsequent lines may be of 
influence in improving PFS and OS data. It should be noted that only 2 PS2 patients received front 
line EGFR-TKI with an unknown EGFR mutational status while the percentage of patients in both 
“morphological” ADC and NSCLC-NOS treated with second/third line EGFR-TKI was quite 
similar (20% versus 16%) making unlikely the influence of any potential bias in PFS and OS 
values. In addition is of note that PFS and OS values reported for “morphological” ADC and IHC 
“favor ADC” subgroups are quite similar to those reported in more recent phase III clinical trials 
testing chemotherapy plus/minus experimental agents in all comers
18,19
.  
Immunohistochemistry allowed to further stratify such apparently undefined tumors, identifying 
32/74 (43%) cases sharing glandular markers. Such cases had a rate of response to chemotherapy 
highly similar to that of morphology only ADC diagnoses (Chi-square test, p=0.3), as well as a 
strongly similar trend in terms of PFS (Mantel-Cox test, p=0.2) and OS (Mantel-Cox test, p=0.3), 
thus confirming their relationship with a glandular differentiated lineage. A small subgroup (9/74 
cases, 12%) showed a squamous carcinoma phenotype after IHC analyses: these cases were not 
further considered, either because of the small size of the group and for being out of the specific 
aim of the study. The remaining cases had a “null” phenotype (25/74 cases, 34% of NSCLC-NOS 
and 11.2% of the whole cohort) that included also nine cases with insufficient material in the block 
to perform IHC and coded as NSCLC-NOS, without impairing the statistical analyses. The survival 
outcome of this group, was significantly worse than those of the above subgroups (p<0.0001), 
although comparable in terms of disease stage and treatment. The response rate (RR) was 
determined by the number of partial responses (PR) recorded over the total amount of cases in this 
group. This value (35%) was quite similar to the value of morphological ADC (31%) probably due 
to some partial responses to therapy recorded in the NSCLC null group in a limited interval time of 
the disease that was not maintained in the overall survival: as a matter of fact the difference 
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between the two groups was greater in term of DCR with a major number of progressive disease 
cases in the undifferentiated group. In NSCLC-NOS the “null phenotype” appears to be an adverse 
prognostic factor on treatment outcome, independently from the type of chemotherapy. These 
findings are not surprising since it is known that large cell carcinomas, according to the WHO 
terminology for surgically resected undifferentiated lung cancers or more in general 
undifferentiated lung carcinomas (i.e sarcomatoid carcinomas) usually follow a more aggressive 
course
20
.  
Nevertheless, it is of clinical interest that undifferentiated carcinomas may be accurately 
characterized using a limited panel of IHC markers in small amounts of tumor tissue. Usually, when 
standard molecular diagnostic procedures are used, these undifferentiated carcinomas do not harbor 
EGFR and ALK abnormalities at a rate as ADC does
21
 and these tumors are only candidates for 
cytotoxic therapy: the use of a cheap additional diagnostic work-up through IHC may allow a better 
treatment customization in today practice, since new drugs with differential activity according to the 
histological type are available. In addition, the identification of a NSCLC-NOS “null” subgroup 
may represent an opportunity for a more in depth assessment of its specific molecular profile.  A 
recently published paper that incorporated in the classification of undifferentiated large cell 
carcinoma the next-generation sequencing technology together with an IHC algorithm, not only 
confirmed several of the IHC assignments but afforded classification in cases where definite 
pathological diagnosis was not possible
22
.  While the value of this approach may become relevant in 
the near future to detect specific gene alterations, it still needs further validation. The technology is 
not available everywhere while the information provided by IHC are readily affordable in routine 
clinical practice. 
An additional value of this report is the possibility of optimally stratifying NSCLC cases even using 
small biopsy samples. The difficulty of defining the subtype based on morphology alone, could 
depend either on the intrinsic features of the tumors or on the amount of diagnostic cells. In this 
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study, 58% of cases were cytological samples, a percentage that rose up to 76% when only the 
NSCLC-“null” category was considered. When processing such samples, it has to be kept in mind 
that the recommended call for a precise immunophenotyping
23
 has to be well balanced with the 
parallel recommended call for preserving tissue for further molecular analyses
24,25
. In fact, an 
accurate subtyping may require, in selected cases, the investigation of multiple markers with the 
consequence of using most if not all the available tissue. Eventually, this will provide a pathological 
characterization of the tumor, to the cost of the possible loss of further chances of molecular 
characterization. A possible solution is to rigorously select the panel of IHC markers when tiny 
biopsies or extremely undifferentiated tumors are analyzed, which are expected to require many 
more markers. In our
14
 and others
24
 experience, the first choice differential markers for glandular 
and squamous lineages should include nuclear markers, which are more easily assessed in small 
specimens, even if suffering from sampling artifacts or poor cellularity due to necrosis. TTF-1 and 
p40 are currently the best options to differentiate adenocarcinoma from squamous carcinoma 
histotypes, respectively. In particular, TTF-1 performs better using 8G7 monoclonal antibody, in 
consideration of its higher specificity
26
, and p40 is superior to p63 again in consideration of its 
higher specificity
27,28
. When both markers turn out to be negative, in approximately 15-20% of 
cases
26
, it is worth testing a second set of markers before concluding for a diagnosis of “null 
phenotype”. To this purpose, rather than relying on specific cytokeratin (CK) types (e.g. CK 7 or 
CK 5&6)
29,30
, we preferred to rely on other lineage markers, that in our
31
 and others'
32,33
 experience 
were associated to a higher specificity. These included Napsin A for adenocarcinoma lineage and 
the desmosomal marker DSC3 for squamous differentiation, which allowed to refine the final 
diagnosis in an additional group of tumors
34
.  
The apparently high rate of NSCLC that retain a “null” phenotype after IHC does not contrast with 
published data
35
 in which the rate of unclassified NSCLC-NOS is reported to be inferior to 10%, 
especially when surgical series only were investigated. In the current series, a small percentage of 
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cases (12%) resulted to be not further characterized for the insufficient number of diagnostic cells 
available for IHC investigations. Despite the official WHO 2004 classification relies on the 
exclusive role of morphology, the combined approach proposed in this retrospective study is totally 
aligned with the recently proposed diagnostic algorithms for NSCLC histotyping in small biopsy or 
cytology samples
36
.  
In conclusion, this study indicates that at least in the group of lung adenocarcinomas, those cases 
categorized as “NSCLC- favor ADC” have a similar clinical behavior as conventionally diagnosed 
ADC. This further supports the validity of a major effort in accurately subtyping all apparently 
undifferentiated lung carcinomas, using a combined morphological and immunophenotypic 
approach in all small biopsy or cytology samples from advanced NSCLC patients.  
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FIGURE LEGENDS 
Figure 1: Distribution graphs of diagnoses prior and after immunohistochemical investigation of 
NSCLC-NOS group. Abbreviations: ADC: adenocarcinoma; NSCLC-NOS: Non Small Cell Lung 
Cancer-Not Otherwise Specified; IHC: Immunohistochemistry; SQC: Squamous Carcinoma.  
Figure 2: Distribution of best responses to first line treatment in the different NSCLC groups. 
Abbreviations: PD: Progressive Disease; PR: Partial Response; SD: Stable Disease; ADC: 
adenocarcinoma; NSCLC: Non Small Cell Lung Cancer; NOS: Not Otherwise Specified; morpho: 
morphological; (m+f): morfhological and favor. 
Figure 3: Kaplan-Meier curves of progression free (PFS) and overall survival (OS) in the patient 
series of morphological ADC and NSCLC-NOS. 
Abbreviations: ADC: adenocarcinoma; NSCLC: Non Small Cell Lung Cancer; NOS: Not 
Otherwise Specified; morpho: morphological. 
Figure 4: Kaplan-Meier curves of progression free (PFS) and overall survival (OS) in the patient 
series after immunohistochemical subtyping: A) PFS and OS of the three separate groups; B) all 
ADC, morphologically and immunohistochemically (m+f) defined were grouped together and 
compared to the group of NSCLC null phenotype. ADC: adenocarcinoma; NSCLC: Non Small Cell 
Lung Cancer; NOS: Not Otherwise Specified. 
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Table 1: Clinical-pathological characteristics of 224 patients. 
Patients 
characteristics 
Overall 
#224  
N (%) 
morpho 
ADC #150 
N (%) 
IHC favour 
ADC #32  
N (%) 
NSCLC 
null #34 
N (%) 
IHC favour 
SQC #8  
N (%) 
Age, median (range) 62 (33-83) 62 (33-81) 65 (51-83) 61 (44-74) 67 (62-73) 
Gender      
Males 156 (70) 102 (68) 21 (66) 25 (74) 8 (100) 
Females 68 (30) 48 (32) 11 (34) 9 (26) 0 
Stage      
IIIB 49 (22) 33 (22) 4 (13) 9 (26) 3 (37) 
IV 175 (78) 117 (78) 28 (87) 25 (74) 5 (63) 
Smoking      
Current 86 (38) 53 (35) 12 (38) 17 (50) 4 (50) 
Former 100 (45) 68 (45) 13 (41) 15 (44) 4 (50) 
No 38 (17) 29 (19) 7 (21) 2 (6) 0 
PS      
0 160 (71) 110 (73) 19 (59) 25 (74) 6 (75) 
1 58 (26) 36 (24) 12 (38) 9 (26) 1 (25) 
2 6 (3) 4 (3) 1 (3) 0 1 (25) 
Tissue sample      
Histological biopsies 94 (42) 72 (48) 10 (31) 8 (24) 4 (50) 
Cytological blocks 130 (58) 78 (52) 22 (69) 26 (76) 4 (50) 
Treatments      
Plat doublet+GEM 63 (28) 45 (30) 5 (16) 8 (23) 5 (63) 
Plat doublet+TAX 30 (13) 19 (13) 3 (9) 5 (15) 3 (37) 
Plat doublet+PEM 23 (10) 19 (13) 4 (13) 0 0 
Others* 20 (9) 10 (7) 7 (22) 3 (9) 0 
Clinical trials** 88 (39) 57 (38) 13 (41) 18 (53) 0 
Best response      
CR 0 (0) 0 0 0 0 
PR 73 (32.6) 46 (31) 14 (44) 12 (35) 2 (25) 
SD 72 (32.1) 54 (36) 10 (31) 5 (15) 3 (37.5) 
PD 78 (34.9) 50 (33) 8 (25) 17 (50) 3 (37.5) 
RR (%) 33 31 44 35 25 
DCR (%) 65 67 75 50 63 
Survival      
AWD 11 (5) 10 (7) 1 (3) 0 0 
DOD 213 (95) 140 (93) 31 (97) 34 (100) 8 (100) 
Mean PFS (m) 6.8 7.3 7.1 3.8 7.4 
Mean OS (m) 11.6 12.3 13.1 7.2 9.7 
 
*Others include: monochemotherapy with GEM or PEM, carboplatin-paclitaxel-bevacizumab, 
cisplatin-etoposide. 
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**I line treatments within clinical trials include: carboplatin-paclitaxel-AMG 706 (motesanib), 
carboplatin-paclitaxel-ASA 404 (vadimezan), carboplatin-paclitaxel-CP 751,871 (figitumumab), 
carboplatin-paclitaxel-sorafenib, cisplatin-gemcitabine-SAR240550 (iniparib), cisplatin-PEM-
axitinib, gemcitabine-vandetanib, PEM-pazopanib, compassionate I line erlotinib or gefitinib. 
Abbreviations: ADC: adenocarcinoma; NSCLC-NOS: Non Small Cell Lung Cancer- Not Otherwise 
Specified; CR: Complete Response; PR: Partial Response; SD: Stable Disease; PD: Progressive 
Disease; AWD; Alive With Disease; DOD: Death Of Disease, GEM: Gemcitabine; TAX: Taxanes; 
PEM: Pemetrexed. 
 




